Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Charles River Calls Off Merger with Wuxi PharmaTech

publication date: Jul 30, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
The proposed merger between Charles River Laboratories and WuXi PharmaTech has been canceled. Citing investor concerns about uncertainties surrounding the deal, Charles River has officially withdrawn its $21.25 cash and stock offer for all of WuXi’s shares. The large American firm must now pay its China counterpart a $30 million breakup fee. More details....

Stock Symbols: (NYSE: CRL) (NYSE: WX)



Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors